SCHEMBL23218028

SCHEMBL23218028

CCOC(=O)Cc1c(C)cccc1OCc1coc2ccc(Br)cc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.40
MAPT P10636 3/20 0.37
ALDH1A1 P00352 3/20 0.36
HTT P42858 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
POLB P06746 2/20 0.35
MTNR1A P48039 1/20 0.35
GAA P10253 1/20 0.35
ALOX5 P09917 1/20 0.35
MAOA P21397 2/20 0.35
MAOB P27338 2/20 0.35
PTGER1 P34995 1/20 0.35
HPGD P15428 2/20 0.35
MAPK1 P28482 2/20 0.35
SLC26A3 P40879 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852755 1.00 THRB (0.40) THRBMAPTALDH1A1HTTNPSR1
SCHEMBL23218215 0.91 KMT2A (0.40) THRBMAPTALDH1A1HTTNPSR1
SCHEMBL29852971 0.91 KMT2A (0.40) THRBMAPTALDH1A1HTTNPSR1
SCHEMBL23218641 0.90 PTGER1 (0.39) THRBMAPTALDH1A1HTTNPSR1
Hexane SCHEMBL23219247 0.87 PTGER1 (0.37) THRBMAPTALDH1A1HTTNPSR1
Hexane SCHEMBL31615131 0.87 PTGER1 (0.37) THRBMAPTALDH1A1HTTNPSR1
SCHEMBL23218949 0.87 TBXAS1 (0.41) MAPTALDH1A1HTTNPSR1MEN1
SCHEMBL29853258 0.85 THRB (0.41) THRBMAPTALDH1A1HTTNPC1
SCHEMBL23218680 0.85 THRB (0.41) THRBMAPTALDH1A1HTTNPC1
SCHEMBL23218033 0.83 CFD (0.43) THRBMAPTMEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB THRB 2013/4885MAPT 4793/4885ALDH1A1 2667/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB THRB 3892/4885MAPT 3561/4885ALDH1A1 3142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.